Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

demonstrated encouraging potential in initial clinical studies," said David Tabagari, M.D., Ph.D., the head of Medulla Immunotherapy and Chemotherapy Clinic and principal investigator of the bavituximab breast cancer trial being conducted in the Republic of Georgia. "We are pleased to have the opportunity to conduct the first Phase II trial of this potentially valuable new approach to treating cancer."

Tumor response in this study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with cancer of the breast in 2007 and about 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has recently received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol testing
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... According to a new market report published by ... was valued at USD 3,754.6 million in 2012 and is ... a CAGR of 5.9% from 2013 to 2019. , Nearly ... afflicted by bone and joint disorders, and this number is ... and will continue to increase the demand for orthobiologics. Other ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
(Date:8/29/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the six months ended June 30, 2014. ... dollars and presented under International Financial Reporting Standards ... , Announced top-line results related to the ... subjects enrolled in the Phase 2 iDEAL Study ...
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Mass., Oct. 20 Genstruct Inc., a systems,biology ... to better understand large-scale biology, announced today that,it ... of Engineering. In his,new role, Dr. Ray will ... Genstruct technology platform, customer platforms and the company,s,IT ...
... Senomyx, Inc.,(Nasdaq: SNMX ) will release its third ... the opening of the U.S. financial,markets. The Company will ... that will provide a business update and a review ... 11:00 a.m. Eastern Time (8:00 a.m.,Pacific Time)., To ...
... as President , ... San Diego/Phoenix (PRWEB) October ... based on the products of newborn dermal fibroblasts, today announced the ... growing medical aesthetic industries based on Histogen,s core technology. , , ...
Cached Biology Technology:Genstruct Expands Team with New VP of Engineering 2Genstruct Expands Team with New VP of Engineering 3SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008 2Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market 2Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market 3Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market 4
(Date:8/28/2014)... (LMU) in Munich have assigned a number of ... arthropods. These animals lived in shallow marine habitats ... found in Jurassic strata. , Before they ... habitat and were fossilized some 435 million years ... the Silurian seas although they were not ...
(Date:8/27/2014)... single fungal cell or bacterial colony exerts on a plant ... role in setting up some of the most fundamental symbiotic ... much of a stretch to say that plants may have ... the touch of beneficial fungi, according to a new study ... University of Wisconsin-Madison. , "Many people have studied how ...
(Date:8/27/2014)... short-faced bears, giant ground sloths, saber-toothed cats and American ... ago at the end of the Pleistocene period. The ... by scientists who, until recently, could only speculate as ... Santa Barbara,s James Kennett, professor emeritus in the Department ... Earth played a major role in the extinction. Their ...
Breaking Biology News(10 mins):Paleontology: Oldest representative of a weird arthropod group 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3Nanodiamonds are forever 2Nanodiamonds are forever 3
... the process by which a biological cell divides into ... on that evolution has conserved it across the eons ... the U.S. Department of Energy's Lawrence Berkeley National Laboratory ... that the core machinery for initiating DNA replication is ...
... method to estimate population, have found that there may be ... thought. , The giant panda is one of the world's ... a restricted mountainous region in China with an unusual dietary ... nature has shielded important knowledge needed to save it from ...
... healthy? To answer this, Sea Grant biologists are cracking ... claim: the more parasites, the healthier the marsh. , ... about infectious disease and human health (malaria, for example, ... are investigating are not just any kind of parasite. ...
Cached Biology News:Molecular DNA switch found to be the same for all life 2Molecular DNA switch found to be the same for all life 3Molecular DNA switch found to be the same for all life 4Molecular DNA switch found to be the same for all life 5Brighter future for giant panda? 2Even a little cooling helps after cardiac arrest 2Even a little cooling helps after cardiac arrest 3
... formulated for non-denaturing polyacrylamide and agarose gel ... solution contains a bromophenol blue tracking dye ... sample loading. EDTA has been included to ... SDS has been added to help dissociate ...
... Antibody Description: ... antibody. Detects 70 kDa YAP from ... and immunohistochemistry. ... Storage: -20C ...
...
... M-PER Mammalian Protein Extraction ... cell lysis solution that means ... and no sonication! With M-PER ... just five minutes at room ...
Biology Products: